Eyes with fibrovascular PEDs may be at increased risk for the development of an RPE tear following anti-VEGF therapy, especially for PEDs greater than 600 μm in height. The mechanism for the tear is believed to be contraction of the underlying type 1 CNV, resulting from the anti-VEGF drug action.